Teva has offered to buy Mylan in a cash-and-stock deal valued at about $40.1 billion. The potential combination would result in a powerhouse of a generic drug developer competing against rivals such as …
Teva has offered to buy Mylan in a cash-and-stock deal valued at about $40.1 billion. The potential combination would result in a powerhouse of a generic drug developer competing against rivals such as …